Fund strategy
The investment objective of this Sub-fund is to preserve capital and achieve long-term capital growth primarily by investing mainly throughout the biotechnology sector and in particular within the generic pharmaceuticals, large pharmaceuticals and specialty pharmaceuticals sub-sectors, across geographies and market capitalisations. North America, Nasdaq and small and mid-capitalized companies will be respectively the main geography, market and capitalisation focus of the Sub-Fund.
Performance
Fees and Expenses
Total Returns
Fund's details
Geographical Distribution
Fund's portfolio distribution among the different geographical areas.
| United States of America | 78,99% | |
| SWITZERLAND | 6,46% | |
| ISRAEL | 1,58% |
By investments
Fund's investments distribution.
| Editas Medicine Inc Ord | 7,05% |
| Crispr Therapeutics Ag Ord | 6,46% |
| Ardelyx Inc Ord | 5,49% |
| Intuitive Surgical Inc Ord | 4,79% |
| Arcutis Biotherapeutics Inc Ord | 4,77% |
| Phathom Pharmaceuticals Inc Ord | 4,72% |
| Personalis Inc Ord | 4,72% |
| Nanostring Technologies Inc Ord | 4,26% |
| Scpharmaceuticals Inc Ord | 4,24% |
| 89bio Inc Ord | 4,21% |
By sector
Fund's possitions distribution by the sdctor they belong to.
| Healthcare | 87,04% |
| Non Classified Equity | 0,31% |
Biotechnology
